Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Constantin Lapa - , Universitätsklinikum Würzburg (Autor:in)
  • Heribert Hänscheid - , Universitätsklinikum Würzburg (Autor:in)
  • Malte Kircher - , Universitätsklinikum Würzburg (Autor:in)
  • Andreas Schirbel - , Universitätsklinikum Würzburg (Autor:in)
  • Gerd Wunderlich - , Klinik und Poliklinik für Kinder- und Jugendmedizin (Autor:in)
  • Rudolf A. Werner - , Universitätsklinikum Würzburg (Autor:in)
  • Samuel Samnick - , Universitätsklinikum Würzburg (Autor:in)
  • Jörg Kotzerke - , Klinik und Poliklinik für Nuklearmedizin (Autor:in)
  • Hermann Einsele - , Division of Hematology and Medical Oncology (Autor:in)
  • Andreas K. Buck - , Universitätsklinikum Würzburg (Autor:in)
  • Hans-Jürgen Wester - , Technische Universität München (Autor:in)
  • Götz Ulrich Grigoleit - , Division of Hematology and Medical Oncology (Autor:in)

Abstract

We have recently reported on our experience with C-X-C-motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pretreated relapsed diffuse large B-cell lymphoma (3 men, 3 women; aged, 54 ± 8 y) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation. In 2 patients, radioimmunotherapy targeting CD20 or CD66 was added to enhance antilymphoma activity. Endpoints were incidence and severity of adverse events, progression-free survival, and overall survival. Results: RLT and additional radioimmunotherapy were well tolerated, without any acute adverse events or changes in vital signs. Successful engraftment was recorded after a median of 11 d (range, 9-13 d). Of the 4 patients who were available for follow-up (one patient died of CNS aspergillosis 29 d after RLT and another of sepsis in aplasia 34 d after RLT), CXCR4-directed RLT resulted in a partial response in two (both treated with additional radioimmunotherapy) and a mixed response in the remaining two. The response duration was rather short-lived, with a median progression-free survival of 62 d (range, 29-110 d) and a median overall survival of 76 d (range, 29-334 d). Conclusion: CXCR4-directed RLT (in combination with additional radioimmunotherapy) is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-cell lymphoma.

Details

OriginalspracheEnglisch
Seiten (von - bis)60-64
Seitenumfang5
FachzeitschriftJournal of Nuclear Medicine
Jahrgang60
Ausgabenummer1
PublikationsstatusVeröffentlicht - Jan. 2019
Peer-Review-StatusJa

Externe IDs

Scopus 85052063059

Schlagworte

Schlagwörter

  • Feasibility Studies, Female, Humans, Ligands, Lymphoma, Large B-Cell, Diffuse/metabolism, Male, Middle Aged, Radiometry, Receptors, CXCR4/metabolism, Safety, Stem Cell Transplantation, Treatment Outcome

Bibliotheksschlagworte